From the Research
The MATTERHORN study is not directly mentioned in the provided evidence, however, based on the most recent and highest quality study available, which is the RE-SPIRE trial 1, it can be inferred that the treatment of acute pulmonary embolism is a complex process that involves various anticoagulant therapies. The RE-SPIRE trial compared the efficacy and safety of dabigatran versus warfarin in patients with high and intermediate to high acute pulmonary embolism risk after endovascular mechanical thrombus fragmentation procedure with reduced-dose thrombolysis (CDT+RDT) 1.
- The study found that dabigatran was comparable in effectiveness to warfarin, with a similar decrease in mean pulmonary artery pressure and deep vein thrombosis dynamics.
- However, dabigatran had greater safety compared to warfarin, with fewer nonmajor bleeding events.
- The results of the study suggest that dabigatran may be recommended for the treatment and prevention of pulmonary embolism after CDT with RDT in patients with high and intermediate to high pulmonary embolism risk. It is essential to note that the provided evidence does not directly discuss the MATTERHORN study, and the information available is based on other studies, such as the RE-SPIRE trial 1.
- The treatment of pulmonary embolism should be individualized, taking into account the patient's risk factors, bleeding risk, and other comorbidities.
- The choice of anticoagulant therapy should be based on the most recent and highest quality evidence available, such as the RE-SPIRE trial 1. In conclusion, while the MATTERHORN study is not directly mentioned in the provided evidence, the treatment of acute pulmonary embolism is a complex process that involves various anticoagulant therapies, and the choice of therapy should be based on the most recent and highest quality evidence available, such as the RE-SPIRE trial 1.